Methods of Subtyping CRC and their Association with Treatment of Colon Cancer Patients with Oxaliplatin

摘要

A gene expression signature identifies stage II colon cancer patients who will receive benefit from oxaliplatin. Oxaliplatin has been shown to lengthen the survival of colon cancer patients, when it is combined with 5-fluorouracil plus leucovorin (FULV) in NSABP clinical trial C-07. Gene expression signatures are used first to classify tumors with regard to their respective subtypes, enterocyte, TA, goblet, inflammatory and stem-like and detection of expression of the enterocyte subtype directs treatment of the patient with oxaliplatin.

主权项

1. A method for treating colon cancer in a patient in need thereof said method comprising:
obtaining a tumor tissue sample from said patient; determining a gene expression signature of said sample; identifying a tumor tissue subtype or sub-subtype from said gene expression signature; and administering oxaliplatin when the identified minor tissue subtype or sub-subtype is an oxidiplatin responsive subtype or sub-subtype.